Dalbavancin

Dec 11, 2019

Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value

Nov 25, 2019

Correvio to Present at the Piper Jaffray 31st Annual Healthcare Conference

Sep 27, 2019

Correvio to Present at the 2019 Cantor Global Healthcare Conference

Aug 08, 2019

Correvio to Report Second Quarter 2019 Financial Results

Apr 03, 2019

Correvio Announces Xydalba(TM) (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019

Mar 07, 2019

Correvio to Present at Upcoming Investor Conferences

Feb 21, 2019

Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

Nov 20, 2018

Correvio to Present at the 30th Annual Piper Jaffray Healthcare Conference

Apr 12, 2018

Cardiome Announces Fifteen Xydalba(TM) and Zevtera® Abstracts at ECCMID 2018

Mar 22, 2018

Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review

Dec 11, 2017

Cardiome Announces Xydalba(TM) Treatment And Patient Experience Presentations At The 2017 National Opat Conference

Oct 30, 2017

Cardiome Announces Commercial Launch of Xydalba(TM) in Three New European Geographies

Sep 12, 2017

Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

Jun 21, 2017

Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel